Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
News Corp Extends Contract with Chief Executive Robert Thomson
-
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
-
CODI DEADLINE: ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Compass Diversified Holdings Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - CODI
-
PFMCrypto Launches Revolutionary XRP Mining Contracts, Igniting Market Enthusiasm
-
CAR DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 24 Deadline in Securities Class Acti
-
CIVI DEADLINE: ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Civitas Resources, Inc. Investors to Secure Counsel Before Important July 1 Deadline in Securities Class Action - CIVI
-
RDDT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Reddit, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
CODI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Compass Diversified Holdings Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
NSSC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that NAPCO Security Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
CAR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Avis Budget Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
-
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
-
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DDD
-
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
-
Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy
-
Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGN
-
ROSEN, A LEADING AND RANKED FIRM, Encourages Bitfarms Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BITF
-
Couple Rides 9100 km from Mexico to Alaska to Set World Record in 80 days to Ignite Humanity and Inspire Global Education
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Bancorp, Inc. Investors to Inquire About Securities Class Action Investigation - EGBN
-
Oklahoma City (OK) Mayor David Holt Elected New President of the U.S. Conference of Mayors, Policy Agenda Adopted for the Year Ahead, as Annual Meeting Concludes
-
From Cult Thriller to Real-Life Dares: The Producers of Would You Rather Launch CAJOLE -- A Platform Asking How Far You'd Go for the Right Price
-
ROSEN, A LONGSTANDING FIRM, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PEPG
-
State Launches State Echo: An Agentic AI Platform for Insurance Follow-Up and Denials Management
-
FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance
-
Bitget Partners with MotoGP for a High-Speed Collision of Tech and Speed
-
Monster Energy Athletes Claim Victories and Make Action Sports History On the Final Day of X Games Osaka 2025
-
INVESTOR NOTICE: Apple Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AAPL
-
ELV Investors Have the Opportunity to Lead the Elevance Health Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
DMRC DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Digimarc Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DMRC
-
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Reckitt Benckiser Group PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action - RBGLY
-
Detroit Coney Grill: Your Go-To Spot for Michigan Sports in Arizona
-
WST DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WST
-
PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Vestis Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - VSTS
-
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
-
WST Investors Have the Opportunity to Lead the West Pharmaceutical Services Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
Vestis Investors Have the Opportunity to Lead the Vestis Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
-
From Grit to Glory: Rockford Hosts Illinois' First IRONMAN, Cementing Its Role on the National Sports Stage
-
CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
-
CagriSema Demonstrates Significant Weight Loss in Adults with Obesity
-
ZiiGaat Launches Luna: 6-BA Driver Studio IEM for True Audio Professionals
-
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
OGN Investors Have the Opportunity to Lead the Organon Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
FTRE Investors Have the Opportunity to Lead the Fortrea Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
DV Investors Have the Opportunity to Lead the DoubleVerify Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
LPRO Investors Have the Opportunity to Lead the Open Lending Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
